The importance of endothelin-I for microvascular dysfunction in diabetes

Vascular Health and Risk Management

Volumn 4, Issue 5, 2008, Pages 1061-1068

  Kalani, Majid ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

Diabetes mellitus; Diabetic microangiopathy; Endothelin 1; ETA receptor antagonist; Microcirculation

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; CARDIOVASCULAR AGENT; ENDOTHELIN RECEPTOR;

DIABETIC FOOT; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; ENDOTHELIAL DYSFUNCTION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; VASOCONSTRICTION; DIABETIC ANGIOPATHY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MICROCIRCULATION; TREATMENT OUTCOME; UPREGULATION;

CARDIOVASCULAR AGENTS; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; ENDOTHELIN-1; HUMANS; MICROCIRCULATION; RECEPTORS, ENDOTHELIN; TREATMENT OUTCOME; UP-REGULATION;

EID: 56849101712     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Abassi ZA, Tate JE, Golomb E, et al. 1992. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension, 20:89-95.
2. B -receptor blockade in humans. J Appl Physiol, 93:2112-21.
3. Ak G, Buyukberber S, Sevinc A, et al. 2001. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with type 2 diabetes mellitus. J Diabetes Complications, 15:150-7.
4. Anfossi G, Russo I, Doronzo G, et al. 2007. Relevance of the vascular effects of insulin in the rationale of its therapeutical use. Cardiovasc Hematol Disord Drug Targets, 7:228-49.
5. Anggard E, Galton S, Rae G, et al. 1989. The fate of radioiodinated endothelin-1 and endothelin-3 in the rat. J Cardiovasc Pharmacol, 13:S46-S49.
6. Berti-Mattera LN, Gariepy CE, Burke RM, et al. 2006. Reduced expression of endothelin B receptors and mechanical hyperalgesia in experimental chronic diabetes. Exp Neurol, 201:399-406.
7. Boulton AJ, Scarpello JH, Ward JD. 1982. Venous oxygenation in the diabetic neuropathic foot: evidence of arteriovenous shunting? Diabetologia, 22:6-8.
8. Caballero AE, Arora S, Saouaf R, et al. 1999. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes, 48:1856-62.
9. Cameron NE, Cotter MA, Low PA. 1991. Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am J Physiol, 261:E1-E8.
10. Cameron NE, Cotter MA. 1995. Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest, 96:1159-63.
11. Candido R, Allen TJ. 2002. Haemodynamics in microvascular complications in type 1 diabetes. Diabetes Metab Res Rev, 18:286-304.
12. Cardillo C, Kilcoyne CM, Cannon RO, et al. 2000. Increased activity of endogenous endothelin in patients with hypercholesterolemia. J Am Coll Cardiol, 36:1483-8.
13. Cardillo C, Kilcoyne CM, Waclawiw M, et al. 1999. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension, 33:753-8.
14. Chade AR, Krier JD, Textor SC, et al. 2006. Endothelin-A receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia. J Am Soc Nephro, 17:3394-403.
15. Chakrabarti S, Gan XT, Merry A, et al. 1998. Augmented retinal endothelin-1, endothelin-3, endothelinA and endothelinB gene expression in chronic diabetes. Curr Eye Res, 17:301-7.
16. Chakrabarti S, Sima AA. 1997. Endothelin-1 and endothelin-3-like immuno-reactivity in the eyes of diabetic and non-diabetic BB/W rats. Diabetes Res Clin Pract, 37:109-20.
17. Cooper ME. 1998. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet, 352(9123):213-19.
18. Cowburn PJ, Cleland JG, McArthur JD, et al. 1999. Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction. J Am Coll Cardiol, 33:932-8.
19. Creager MA, Luscher TF, Cosentino F, et al. 2003. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation, 108:1527-32.
20. De Mattia G, Cassone-Faldetta M, Bellini C, et al. 1998. Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. Am J Hypertens, 11:983-8.
21. Donatelli M, Colletti I, Bucalo ML, et al. 1994. Plasma endothelin levels in NIDDM patients with macroangiopathy. Diabetes Res, 25:159-64.
22. Fagrell B, Jorneskog G, Intaglietta M. 1999. Disturbed microvascular reactivity and shunting - a major cause for diabetic complications. Vasc Med, 4:125-7.
23. Fegan PG, Tooke JE, Gooding KM, et al. 2003. Capillary pressure in subjects with type 2 diabetes and hypertension and the effect of antihypertensive therapy. Hypertension, 41:1111-17.
24. Gall MA, Rossing P, Skott P, et al. 1991. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia, 34:655-61.
25. Giannini C, Dyck PJ, 1995. Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Ann Neurol, 37:498-504.
26. Gokin AP, Fareed MU, Pan HL, et al. 2001. Local injection of endothelin-1 produces pain-like behaviour and excitation of nociceptors in rats. J Neurosci, 21:5358-66.
27. Groop PH, Forsblom C, Thomas MC, 2005. Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab, 1:100-10.
28. Gundersen HJG. 1974. Peripheral blood flow and metabolic control in juvenile diabetes. Diabetologia, 10:225-31.
29. Halcox JP, Nour KR, Zalos G, et al. 2001. Coronary vasodilation and improvement in endothelial dysfunction with endothelin ET(A) receptor blockade. Circ Res, 89:969-76.
30. Jaap AJ, Hammersley MS, Shore AC, 1994. Reduced microvascular hyperaemia in subjects at risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia, 37:214-16.
31. Jansson P-A. 2007. Endothelial dysfunction in insulin resistance and type 2 diabetes. J Intern Med, 262:173-83.
32. Jarvis MF, Wessale JL, Zhu CZ, et al. 2000. ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. Eur J Pharmacol, 388:29-35.
33. Jeffcoate WJ, Harding KG. 2003. Diabetic foot ulcers. Lancet, 361:1545-51.
34. Johnström P, Fryer TD, Richards HK, et al. 2005. Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ET B receptors in vivo. Br J Pharmacol, 144:115-22.
35. Jörneskog G, Brismar K, Fagrell B. 1995. Skin capillary circulation is more impaired in toes of diabetic than non-diabetic patients with peripheral vascular disease. Diabet Med, 12:36-41.
36. Jörneskog G, Brismar K, Fagrell B. 1998. Pronounced skin capillary ischemia in the feet of diabetic patients with bad metabolic control. Diabetologia, 41:410-15.
37. Jörneskog G, Kalani M, Kuhl J, et al. 2005. Early microvascular dysfunction in healthy normal-weight males with heredity for type 2 diabetes. Diabetes Care, 28:1495-7.
38. Jörneskog G. 1995. Functional Microangiopathy in the Digital Skin of Patients with Diabetes Mellitus [dissertation]. Stockholm, Sweden: Karolinska Institute.
39. Kalani M, Brismar K, Fagrell B, et al. 1999. Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. Diabetes Care, 22:147-51.
40. Kalani M, Pernow J, Bragd J, et al. 2008. Improved peripheral perfusion during endothelin-A receptor blockade in patients with type 2 diabetes and critical limb ischemia. Diabetes Care, 31:e56.
41. Kalani M, Silveira A, Blombäck M, et al. 2007. Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. Thromb Res, 120:653-61.
42. Khan ZA, Chakrabarti S. 2003. Endothelins in chronic diabetic complications. Can J Physiol Pharmacol, 81:622-34.
43. King H, Aubert RE, Herman WH. 1998. Global burden of diabetes 1995-2025: prevalence, numerical estimates and projections. Diabetes Care, 21:1414-31.
44. Kohan DE. 1997. Endothelins in the normal and diseased kidney. Am J Kidney Dis, 29:2-26.
45. Kohner EM, Patel V, Rassam SM. 1995. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes, 44:603-7.
46. Kyriakides ZS, Kremastinos DT, Bofilis E, et al. 2000. Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography. Heart, 84:176-82.
47. Lee YJ, Shin SJ, Tsai JH. 1994. Increased urinary endothelin-1-like immunoreactivity in NIDDM patients with albuminuria. Diabetes Care, 17:263-6.
48. Li L, Fink GD, Watts SW, et al. 2003. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation, 107:1053-8.
49. Love MP, Ferro CJ, Haynes WG, et al. 2000. Endothelin receptor antagonism in patients with chronic heart failure. Cardiovasc Res, 47:166-72.
50. Low PA, Lagerlund TD, MeManis PG. 1989. Nerve blood flow and oxygen delivery in normal, diabetic, and ischemic, neuropathy. Int Rev Neurobiol, 31:355-438.
51. Luscher TF, Creager MA, Beckman JA, et al. 2003. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation, 108:1655-61.
52. Masuzawa K, Jesmin S, Maeda S, et al. 2006. Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina. Exp Biol Med, 231:1090-4.
53. Mather KJ, Mirzamohammadi B, Lteif A, et al. 2002. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes, 51:3517-23.
54. Molenaar P, O'Reilly G, Sharkey A, et al. 1993. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res, 72:526-38.
55. Nohria A, Garrett L, Johnson W, et al. 2003. Endothelin-1 and vascular tone in subjects with atherogenic risk factors. Hypertension, 42:43-8.
56. Pang IH, Yorio T. 1997. Ocular actions of endothelins. Proc Soc Exp Biol Med, 215:21-34.
57. Pernow J, Bohm F, Johansson BL, et al. 2000. Enhanced vasoconstrictor response to endothelin-B-receptor stimulation in patients with atherosclerosis. J Cardiovasc Pharmacol, 36:S418-S20.
58. Properzi G, Terenghi G, Gu XH, et al. 1995. Early increase precedes a depletion of endothelin-1 but not of von Willebrand factor in cutaneous microvessels of diabetic patients; a quantitative immunohistochemical study. J Pathol, 175:243-52.
59. Rask-Madsen C, King GL, 2007. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab, 3:46-56.
60. Rayman G, Williams SA, Spencer PD, et al. 1986. Impaired microvascular hyperaemic response to minor skin trauma in type 1 diabetes. Br Med J, 292:1295-8.
61. Resink TJ, Hahn AWA, Scott-Burden T, et al. 1990. Inducible endothelin messenger RNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem Biophys Res Commun, 168:1303-10.
62. Romero M, Jiménez R, Sánchez M, et al. 2008. Quercetin inhibits vascular superoxide production induced by endothelin-1: Role of NADPH oxidase, uncoupled eNOS and PKC. Atherosclerosis, Mar 16 [Epub ahead of print].
63. Sakurai T, Yanagisawa M, Masaki T. 1992. Molecular characterization of endothelin receptors. Trends Pharmacol Sci, 13:103-8.
64. Sandeman DD, Pym CA, Green EM, et al. 1991. Microvascular vasodilatation in feet of newly diagnosed non-insulin dependent diabetic patients. Br Med J, 302:1122-3.
65. Sasser JM, Sullivan JC, Hobbs JL, et al. 2007. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol, 18:143-54.
66. Seo B, Oemar BS, Siebenmann R, et al. 1994. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation, 89:1203-8.
67. Settergren M, Pernow J, Brismar K, et al. 2008. Endothelin-A receptor blockade improves nutritive skin capillary circulation in patients with type 2 diabetes and albuminuria. J Vasc Res, 45:295-302.
68. Shore AC, Jaap AJ, Tooke JE. 1994. Capillary pressure in patients with NIDDM. Diabetes, 43:1198-202.
69. Siren AL, Lewczuk P, Hasselblatt M, et al. 2002, Endothelin B receptor deficiency augments neuronal damage upon exposure to hypoxia-ischemia in vivo. Brain Res, 945:144-9.
70. Strachan FE, Spratt JC, Wilkinson IB, et al. 1999. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension, 33:581-5.
71. Takahashi K, Ghatei MA, Lam HC, et al. 1990. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia, 33:306-10.
72. Thrainsdottir S, Malik RA, Dahlin LB, et al. 2003. Endoneurial capillary abnormalities presage deterioration of glucose tolerance and accompany peripheral neuropathy in man. Diabetes, 52:2615-22.
73. Tooke JE, Hanneman MM. 2000. Adverse endothelial function and the insulin resistance syndrome. J Int Med, 247:425-31.
74. Tooke JE. 1983. Capillary pressure in non-insulin-dependent diabetes. Int Angiol, 2:167-71.
75. Tooke JE. 1983. Microvascular haemodynamics in diabetes mellitus. Clin Sci, 70:119-25.
76. Tooke JE. 1995. Microvascular function in human diabetes. A physiological perspective. Diabetes, 44:721-6.
77. Tooke JE. 2000. Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. J Diabetes Complications, 14:197-200.
78. Tur E, Yosipovitch, Bar-On Y. 1991. Skin reactive hyperaemia in diabetic patients. A study by laser Doppler flowmetry. Diabetes Care, 14:958-62.
79. Tymms DJ, Tooke JE. 1988. The effect of continuous subcutaneous insulin infusion (CSII) on microvascular blood flow in diabetes mellitus. Int J Microcirc Clin Exp, 7:347-56.
80. Verhaar MC, Strachan FE, Newby DE, et al. 1998. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation, 97:752-6.
81. Walmsley D, Wales JK, Wiles PG. 1989. Reduced hyperaemia following skin trauma: evidence for an impaired microvascular response to injury in the diabetic foot. Diabetologia, 32:736-9.
82. Wedgwood S, McMullan DM, Bekker JM, et al. 2001. Role for endothelin-1-induced superoxide and peroxynitrite production in rebound pulmonary hypertension associated with inhaled nitric oxide therapy. Circ Res, 89:357-64.
83. Yanagisawa M, Kurihara H, Kimura S, et al. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332:411-15.
84. Zanatta CM, Gerchman F, Burttet L, et al. 2008. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diab Res Clin Pract, 80:299-304.